NO3083633T3 - - Google Patents

Info

Publication number
NO3083633T3
NO3083633T3 NO14815318A NO14815318A NO3083633T3 NO 3083633 T3 NO3083633 T3 NO 3083633T3 NO 14815318 A NO14815318 A NO 14815318A NO 14815318 A NO14815318 A NO 14815318A NO 3083633 T3 NO3083633 T3 NO 3083633T3
Authority
NO
Norway
Application number
NO14815318A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3083633T3 publication Critical patent/NO3083633T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14815318A 2013-12-19 2014-12-16 NO3083633T3 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198604 2013-12-19
PCT/EP2014/077858 WO2015091411A1 (en) 2013-12-19 2014-12-16 Spiro-oxazolones
EP14815318.2A EP3083633B1 (en) 2013-12-19 2014-12-16 Spiro-oxazolones

Publications (1)

Publication Number Publication Date
NO3083633T3 true NO3083633T3 (lt) 2018-04-28

Family

ID=49876427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14815318A NO3083633T3 (lt) 2013-12-19 2014-12-16

Country Status (35)

Country Link
US (3) US10479796B2 (lt)
EP (1) EP3083633B1 (lt)
JP (1) JP6530407B2 (lt)
KR (1) KR102353431B1 (lt)
CN (1) CN105814062B (lt)
AR (1) AR098783A1 (lt)
AU (1) AU2014364729B2 (lt)
BR (1) BR112016013058B1 (lt)
CA (1) CA2932063C (lt)
CL (1) CL2016001495A1 (lt)
CR (1) CR20160215A (lt)
DK (1) DK3083633T3 (lt)
EA (1) EA029167B1 (lt)
ES (1) ES2657994T3 (lt)
HK (1) HK1223920A1 (lt)
HR (1) HRP20180160T1 (lt)
HU (1) HUE036203T2 (lt)
IL (1) IL245464B (lt)
LT (1) LT3083633T (lt)
MA (1) MA39139B1 (lt)
MX (1) MX370663B (lt)
MY (1) MY177313A (lt)
NO (1) NO3083633T3 (lt)
NZ (1) NZ719765A (lt)
PE (1) PE20160864A1 (lt)
PH (1) PH12016500919A1 (lt)
PL (1) PL3083633T3 (lt)
PT (1) PT3083633T (lt)
RS (1) RS56791B1 (lt)
SG (1) SG11201604915PA (lt)
SI (1) SI3083633T1 (lt)
TW (1) TWI548639B (lt)
UA (1) UA117273C2 (lt)
WO (1) WO2015091411A1 (lt)
ZA (1) ZA201603221B (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201600522A (zh) * 2014-02-20 2016-01-01 赫孚孟拉羅股份公司 螺-唑酮
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
AR127706A1 (es) 2021-11-19 2024-02-21 Hoffmann La Roche Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1566384B1 (en) * 2002-11-29 2009-06-17 Banyu Pharmaceutical Co., Ltd. Novel azole derivatives
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
DE602007006989D1 (en) * 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate
CA2674518A1 (en) * 2006-12-22 2008-07-03 F.Hoffmann-La Roche Ag Spiro-piperidine derivatives
ATE536356T1 (de) * 2007-01-12 2011-12-15 Hoffmann La Roche Spiropiperidin-glycinamid-derivate
WO2010054961A1 (en) * 2008-11-13 2010-05-20 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes

Also Published As

Publication number Publication date
SG11201604915PA (en) 2016-07-28
KR20160098490A (ko) 2016-08-18
PE20160864A1 (es) 2016-09-03
MY177313A (en) 2020-09-11
TWI548639B (zh) 2016-09-11
CN105814062A (zh) 2016-07-27
CR20160215A (es) 2016-07-15
UA117273C2 (uk) 2018-07-10
AU2014364729A1 (en) 2016-05-26
CA2932063C (en) 2023-03-07
RS56791B1 (sr) 2018-04-30
JP6530407B2 (ja) 2019-06-12
PH12016500919B1 (en) 2016-06-27
BR112016013058B1 (pt) 2021-02-23
ES2657994T3 (es) 2018-03-07
SI3083633T1 (en) 2018-02-28
AR098783A1 (es) 2016-06-15
IL245464A0 (en) 2016-06-30
PT3083633T (pt) 2018-01-25
EP3083633B1 (en) 2017-11-29
MX370663B (es) 2019-12-19
US20170008901A1 (en) 2017-01-12
US10479796B2 (en) 2019-11-19
HK1223920A1 (zh) 2017-08-11
US20230106150A1 (en) 2023-04-06
HRP20180160T1 (hr) 2018-02-23
MA39139A1 (fr) 2018-05-31
HUE036203T2 (hu) 2018-06-28
DK3083633T3 (da) 2018-01-29
AU2014364729B2 (en) 2018-11-22
KR102353431B1 (ko) 2022-01-20
EA029167B1 (ru) 2018-02-28
EA201691189A1 (ru) 2016-10-31
PL3083633T3 (pl) 2018-04-30
MX2016007809A (es) 2016-09-07
TW201536790A (zh) 2015-10-01
US20200039997A1 (en) 2020-02-06
IL245464B (en) 2019-10-31
WO2015091411A1 (en) 2015-06-25
CL2016001495A1 (es) 2016-12-16
PH12016500919A1 (en) 2016-06-27
EP3083633A1 (en) 2016-10-26
ZA201603221B (en) 2022-05-25
LT3083633T (lt) 2018-02-12
MA39139B1 (fr) 2019-01-31
CN105814062B (zh) 2018-04-24
NZ719765A (en) 2022-04-29
JP2017502028A (ja) 2017-01-19
US11578077B2 (en) 2023-02-14
CA2932063A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
BR112016001600A2 (lt)
BR112015007533A2 (lt)
BR112014017733A2 (lt)
BR112014018502A2 (lt)
BR112014017739A2 (lt)
BR112014019326A2 (lt)
BR112014018516A2 (lt)
BR112014020341A2 (lt)
BR112014018480A2 (lt)
BR112014017855A2 (lt)
BR112014017765A2 (lt)
BR112014017669A2 (lt)
BR112014021878A2 (lt)
BR112014018468A2 (lt)
BR112014018207A2 (lt)
BR112014017901A2 (lt)
BR112014019204A2 (lt)
BR112015015948A2 (lt)
BR112014017722A2 (lt)
BR112016012443A2 (lt)
BR112016004050A2 (lt)
BR112016000715A2 (lt)
BR112014018578A2 (lt)
BR112014018483A2 (lt)
BR112014017794A2 (lt)